Hypofractionated proton beam therapy for centrally located lung cancer.

Introduction: To clarify the efficacy and safety of hypofractionated proton beam therapy (PBT) for centrally located lung cancer.

Methods: We retrospectively reviewed 39 patients who received hypofractionated [≧3 Gy (relative biological effectiveness: RBE)/fraction] PBT for centrally located cT1-2N0M0 (8th edition) lung cancer between 1999 and 2015. A tumour within 2 cm of the proximal bronchial tree was defined as a centrally located tumour.

Proton beam therapy for olfactory neuroblastoma.

Purpose: To clarify the efficacy and feasibility of proton beam therapy (PBT) for olfactory neuroblastoma (ONB).

Methods And Materials: We retrospectively reviewed 42 consecutive patients who received PBT with curative intent for ONB at National Cancer Center Hospital East from November 1999 to March 2012.

Results: Five patients (12%) had Kadish A disease, nine (21%) had Kadish B, and twenty-eight (67%) had Kadish C.